Streetbeat News

Products Services

NFLX

Netflix Inc. (NASDAQ:NFLX) has announced a project called 'Netflix House', which will allow customers to experience the universe of their favorite TV shows and movies, shop for merchandise, and engage in themed activities. The first two stores are expected to open in the U.S. by 2025. Blockbuster, the former video rental chain, made a humorous comment on the announcement, referencing its own failure to adapt to the digital streaming revolution.

Portfolio Pulse from Ananya Gairola

October 17, 2023 | 2:26 am

MRK

The U.S. Food and Drug Administration (FDA) has approved Merck's (NYSE:MRK) anti-PD-1 therapy, KEYTRUDA, for the treatment of patients with resectable non-small cell lung cancer (NSCLC). The approval is based on data from the Phase 3 KEYNOTE-671 trial, which showed significant improvements in event-free survival (EFS) and overall survival (OS).

Portfolio Pulse from Charles Gross

October 16, 2023 | 11:02 pm

WETG

WeTrade Group Inc. (NASDAQ:WETG) has announced the integration and enhancement of its two business segments in China: Yuetao APP and Haolin Haowu APP. The unified platform will now be known as Yuetao Haowu APP.

Portfolio Pulse from Charles Gross

October 16, 2023 | 9:40 pm

MRO

Marathon Oil has entered into a five-year firm LNG sales agreement with Glencore Energy UK. The agreement pertains to a portion of Marathon Oil's equity natural gas produced from the Alba Field in Equatorial Guinea, and will be effective from January 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 9:06 pm

GMDA

Gamida Cell Ltd. (NASDAQ:GMDA) has reported preliminary data from its Phase 1 study of natural killer (NK) cell therapy candidate GDA-201, showing promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma. The study is designed to evaluate safety and determine the maximum tolerated dose. The company expects full data readout of the Phase 1 study in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:39 pm

CMCSA

COMM

CommScope (NASDAQ:COMM) and Comcast (NASDAQ:CMCSA) have achieved symmetrical 4Gbps speeds in lab testing using CommScope's DOCSIS 4.0 Full-Duplex DOCSIS (FDX) amplifiers. This milestone is part of a multi-year FDX amplifier development effort between the two companies. The solutions developed will provide a cost-effective upgrade path to DOCSIS 4.0 FDX, boosting network capacity and offering multi-Gigabit data rates. The companies' DOCSIS 4.0 FDX developments will be showcased at the SCTE® CableTec Expo® in October 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:17 pm

MSFT

Microsoft Corporation's video game, Minecraft, has sold 300 million copies, making it the best-selling video game of all time. The game's success is attributed to its accessibility, innovation, and cross-platform compatibility. Mojang, the game's developer, has announced a year-long celebration for Minecraft's 15th anniversary.

Portfolio Pulse from Franca Quarneti

October 16, 2023 | 8:12 pm

YMAB

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has announced the publication of a study on naxitamab-based chemoimmunotherapy in patients with chemoresistant high-risk neuroblastoma in the journal Cancers. The study found that early administration of naxitamab-based chemo-immunotherapy significantly improved long-term outcomes. The study's principal investigator suggested that the combination of naxitamab and chemotherapy can overcome chemoresistance when promptly initiated in patients with an incomplete response at the end of induction.

Portfolio Pulse from Happy Mohamed

October 16, 2023 | 8:09 pm

STRO

Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage oncology company, announced that it will have five presentations and one poster at the 14th Annual World ADC Conference in San Diego, October 16-19, 2023. The presentations will cover the development of next-generation ADCs, discovery of novel linker payloads, precision engineering for enhanced therapeutic index, stress-free ADC production, and preclinical development of STRO-003. The poster will discuss site-specific dual conjugation.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:06 pm

ASND

Ascendis Pharma has presented 52-week results from the Phase 3 PaTHway Trial at ASBMR 2023. The results showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms. Bone turnover markers trended toward the normal reference ranges for sex and menopausal status and corresponded to smaller changes in bone mineral density (BMD) through Week 52.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:03 pm